Boostrix Dosage/Direction for Use

Posology: A single 0.5 ml dose of the vaccine is recommended.
Boostrix may be administered from the age of four years onwards.
Boostrix should be administered in accordance with official recommendations and/or local practice regarding the use of vaccines with reduced content of diphtheria, tetanus and pertussis antigens.
Boostrix can be administered to pregnant women during the second or the third trimester in accordance with official recommendations (see Indications/Uses, Use in Pregnancy & Lactation and Pharmacology: Pharmacodynamics under Actions).
Boostrix may also be administered to adolescents and adults with unknown vaccination status or incomplete vaccination against diphtheria, tetanus and pertussis as part of an immunisation series against diphtheria, tetanus and pertussis. Based on data in adults, two additional doses of a diphtheria and tetanus containing vaccine are recommended one and six months after the first dose to maximize the vaccine response against diphtheria and tetanus (see Pharmacology: Pharmacodynamics under Actions).
Boostrix can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine and for whom a booster against diphtheria and pertussis is indicated. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.
Repeat vaccination against diphtheria, tetanus and pertussis should be performed at intervals as per official recommendations (generally 10 years).
Paediatric population: The safety and efficacy of Boostrix in children below 4 years of age have not been established.
Method of administration: Boostrix is for deep intramuscular injection preferably in the deltoid region (see Precautions).